Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,354.40 +121.18 0.80%
S&P 500 1,667.47 +17.00 1.03%
Nasdaq 3,498.97 +33.72 0.97%
Ticker Volume Price Price Delta
STOXX 50 2,807.46 -10.53 -0.37%
FTSE 100 6,713.29 -9.77 -0.15%
DAX 8,409.69 +11.69 0.14%
Ticker Volume Price Price Delta
Nikkei 15,360.80 +222.69 1.47%
Hang Seng 23,493.00 +410.35 1.78%
S&P/ASX 200 5,209.04 +28.26 0.55%
  • Fund Type: Open-End Fund
  • Objective: Sector Fund-Health & Biotech
  • Asset Class: Equity
  • Geographic Focus: U.S.

T Rowe Price Health Sciences Fund Inc

+ Add to Watchlist

PRHSX:US

50.52 USD 0.32 0.64%

As of 09:29:30 ET on 05/17/2013.

Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Snapshot for T Rowe Price Health Sciences Fund Inc (PRHSX)

Year To Date: +22.56% 3-Month: +12.47% 3-Year: +26.68% 52-Week Range: 35.37 - 50.90
1-Month: +5.01% 1-Year: +40.76% 5-Year: +16.01% Beta vs SPX: 0.98

Mutual Fund Chart for PRHSX

No chart data available.
  • PRHSX:US 50.52
  • 1M
  • 1Y
Interactive PRHSX Chart

Previous Close

Fund Profile & Information for PRHSX

T. Rowe Price Health Sciences Fund is an open-end fund incorporated in the USA. The Fund's objective is long-term capital appreciation. The Fund invests at least 80% of net assets in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine or the life sciences.

Inception Date: 12-29-1995 Telephone: 1-800-225-5132
Managers: TAYMOUR R TAMADDON
Web Site: www.troweprice.com

Fundamentals for PRHSX

NAV (on 2013-05-17) 50.52
Assets (M) (on 2013-04-30) 6,514.87
Fund Leveraged N
Minimum Investment 1,000.00
Minimum Subsequent Investment 100.00

Dividends for PRHSX

Dividend Type Income
Dividend Frequency Annual
Last Dividend Net (on 2012-12-17) 0.14
Dividend Yield (ttm) 3.58

Fees & Expenses for PRHSX

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 0.65
Redemption Fee 0.00
12b1 Fee 0.00
Expense Ratio 0.79

Top Fund Holdings for PRHSX

Filing Date: 03/31/2013
Name Position Value % of Total
Gilead Sciences Inc 6,466,100 316,386,273 5.107%
Alexion Pharmaceuticals Inc 3,278,600 302,090,204 4.876%
Catamaran Corp 4,950,000 262,498,500 4.237%
Valeant Pharmaceuticals Intern 2,450,000 183,799,000 2.967%
Pharmacyclics Inc 2,125,000 170,871,250 2.758%
Incyte Corp Ltd 5,290,000 123,838,900 1.999%
UnitedHealth Group Inc 2,100,000 120,141,000 1.939%
Celgene Corp 894,900 103,727,859 1.674%
Regeneron Pharmaceuticals Inc 580,000 102,312,000 1.651%
Onyx Pharmaceuticals Inc 1,105,000 98,190,300 1.585%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Financial Commentaries

Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil